Your browser doesn't support javascript.
loading
An update on the use of gamma (multi)sensory stimulation for Alzheimer's disease treatment.
Manippa, Valerio; Palmisano, Annalisa; Filardi, Marco; Vilella, Davide; Nitsche, Michael A; Rivolta, Davide; Logroscino, Giancarlo.
Afiliação
  • Manippa V; Department of Education, Psychology and Communication, University of Bari Aldo Moro, Bari, Italy.
  • Palmisano A; Department of Psychology and Neurosciences, Leibniz Research Centre for Working Environment and Human Factors, Dortmund, Germany.
  • Filardi M; Department of Education, Psychology and Communication, University of Bari Aldo Moro, Bari, Italy.
  • Vilella D; Department of Basic Medicine, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy.
  • Nitsche MA; Center for Neurodegenerative Diseases and the Aging Brain, University of Bari Aldo Moro at Pia Fondazione "Card. G. Panico", Tricase, Italy.
  • Rivolta D; Center for Neurodegenerative Diseases and the Aging Brain, University of Bari Aldo Moro at Pia Fondazione "Card. G. Panico", Tricase, Italy.
  • Logroscino G; Department of Psychology and Neurosciences, Leibniz Research Centre for Working Environment and Human Factors, Dortmund, Germany.
Front Aging Neurosci ; 14: 1095081, 2022.
Article em En | MEDLINE | ID: mdl-36589536
ABSTRACT
Alzheimer's disease (AD) is characterized by reduced fast brain oscillations in the gamma band (γ, > 30 Hz). Several animal studies show that inducing gamma oscillations through (multi)sensory stimulation at 40 Hz has the potential to impact AD-related cognitive decline and neuropathological processes, including amyloid plaques deposition, neurofibrillary tangles formation, and neuronal and synaptic loss. Therefore Gamma Entrainment Using Sensory stimulation (GENUS) is among the most promising approaches for AD patients' treatment. This review summarizes the evidence on GENUS effectiveness, from animal models to AD patients. Despite the application on human is in its infancy, the available findings suggest its feasibility for the treatment of AD. We discuss such results in light of parameter improvement and possible underlying mechanisms. We finally emphasize the need for further research for its development as a disease-modifying non-pharmacological intervention.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article